Vivo Capital, Leads a $200m Series A Round of Financing in Avistone Pharmaceuticals
-
Vivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) GalleryVivo Capital’s Portfolio Company Aadi BioSceince announced a FDA approval of FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
-
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders Gallery
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders
